BIOMAT Database Logo BIOMAT Database Logo

Electroretinogram in parkinsonism and effects of L-DOPA. 1981

M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D004596 Electroretinography Recording of electric potentials in the retina after stimulation by light. Electroretinographies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
Changes in electroretinogram and serum potassium during L-DOPA treatment in parkinsonism.
January 1983, Archiv fur Psychiatrie und Nervenkrankheiten,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
Effects of L-DOPA on pharmacological parkinsonism.
January 1966, Acta psychiatrica Scandinavica,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
L-dopa and parkinsonism.
August 1970, Journal of the Medical Association of Georgia,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
L-dopa and parkinsonism.
October 1971, Nursing mirror and midwives journal,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
L-Dopa and Parkinsonism.
April 1970, Nature,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
L-dopa and parkinsonism.
January 1971, Hawaii medical journal,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
L-dopa and Parkinsonism.
January 1970, London Clinic medical journal,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
Pyridoxine reversal of L-dopa effects in Parkinsonism.
January 1969, Transactions of the American Neurological Association,
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
Side-effects of L-dopa in postencephalic parkinsonism.
May 1970, Lancet (London, England),
M Filipová, and D Terziivanov, and J Balík, and I Janků, and V Filip, and L Stika, and H Krejcová
Side-effects of L-dopa in postencephalitic parkinsonism.
September 1970, Lancet (London, England),
Copied contents to your clipboard!